References

1. American Heart Association. 1998 Heart and stroke statistical update. Dallas: American Heart Association; 1997.

2. Materson BJ, Reda DG, Cushman WC, et al. Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med 1993;328:914.

3. Yusuf S, Nicklas JM, Timmis G, et al. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 1992;327:685-691.

4. Limacher MC, Yusuf S. Cardiovascular health and disease in women. In: Wenger, Speroff, Packard (eds): Proceedings of an NHLBI Conference. Darien:LeJacq; 1993.

5. Rothman KJ, Greenland S. Modern epidemiology. Philadelphia: Lippincott-Raven Publishers; 1998.

6. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.

7. Hedges LV, Olkin I. Statistical methods for meta-analysis. San Diego: Academic Press, Inc.; 1985.

8. Stata Corporation. Stata Statistical Software. Release 7.0. College Station: Stata Corporation; 2001.

9. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17:2815-2834.

10. SAS Institute, Inc. SAS/STAT. Cary, NC: SAS Institute, Inc.; 1999.

11. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-634.

12. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-1101.

13. Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making 1993;13:89-102.

14. U.S. Bureau of the Census. Statistical abstract of the United States. U.S. Census Bureau: Washington;2000.

15. Bureau of Labor Statistics. Consumer price index. http://www.bls.gov/cpi/home.htm.

16. AAUP policy documents and reports (The Redbook). Baltimore: Johns Hopkins University Press; 2001.

17. Paul SD, Kuntz KM, Eagle KA, Weinstein MC. Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure. Arch Intern Med 1994;154:1143-9.

18. Gold M, Siegel J, Russel L, Weinstein M (eds.). Cost Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.

19. National Center for Health Statistics. United States life tables, 1998 (PHS 2000-1120). Atlanta: Centers for Disease Control and Prevention; 2000.

20. McDonagh TA, Robb SD. Murdoch DR, Morton JJ, Ford I, Morrison, CE, Tunstall-Pedoe H, McMurray JJV, Dargie HJ. N Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998;351:9-13.

21. McDonagh TA, Morrison CE, Lawrence A, et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet 1997; 350:829-33.

22. Naik MM, Diamond GA, Pai T, et al. Correspondence of left ventricular ejection fraction determinations from two-dimensional echocardiography, radionuclide angiography and contrast cineangiography. J Am Coll Cardiol 1995;25:937-42.

23. Schiller NB, Acquatella H, Ports TA, et al. Left ventricular volume from paired biplane two-dimensional echocardiography. Circulation 1979;60:547-55.

24. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.

25. National Center for Health Statistics. Vital Statistics of the United States: Mortality. Atlanta: Centers for Disease Control and Prevention; 1991.

26. American Heart Association. Heart and stroke statistical update. Dallas: American Heart Association; 2000.

27. Glick H, Cook J, Kinosian B, et al. Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the Studies of Left Ventricular Dysfunction (SOLVD) treatment trial. J Cardiac Failure 1995;1:371-380.

28. Cook JR, Glick HA, Gerth W, et al. The cost and cardioprotective effects of enalapril in hypertensive patients with left ventricular dysfunction. Am J Hypertens 1998;11:1433-41.

29. Ball SG, Hall AS, Mackintosh AF, et al. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. the Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993;342 (8875):821-8.

30. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.

31. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327 (10);669-77.

32. Moye LA, Pfeffer MA, Wun CC, et al. Uniformity of captopril benefit in the SAVE study: subgroup analysis. Eur Heart J 1994;15:2-8.

33. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995;332:80-85.

34. Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Eng J Med 2001;344:1351-7.

35. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995;333(25):1670-6.

36. The Beta-Blocker Evaluation of Survival Trial Investigators (BEST): a trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659-67.

37. Eichhorn EJ, Domanski MJ, Adams K, et al. Effect of beta-blockade on mortality in African-Americans: the beta-blocker evaluation of survival trial. Circulation 2000;102(suppl 2):18.

38. Plehn JF, Krause-Steinrauf H, Anand IS, et al. Effect of race on cause-specific cardiovascular mortality in BEST. Circulation 2000;102(suppl 2):18.

39. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.

40. Erdmann E, Lechat P, Verkenne P, Wiemann H. Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Euro J Heart Failure 2001;3:469-479.

41. Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8.

42. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-2007.

43. Wedel H, DeMets D, Deedwania P, et al. Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HR trial. Am Heart J 2001;142:502-11.

44. Ghali JK, Pina IL, Gottlieb SS, et al. Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). Circulation 2002;105:1585-91.

45. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349-55.

46. Yancy CW, Fowler MB, Colucci WS, et al. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med 2001;344:1358-65.